The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.
histologically verified, localized prostate cancer without regional lymphadenopathy or distant metastases
low or intermediate risk - favorable risk
low risk: no staging required
intermediate risk- favorable risk: CT abdomen and pelvis
a histological type other than acinar adenocarcinoma
the presence of local lymphadenopathy or distant metastases
a dominant lesion in the periphery that is in contact with the capsule or grows through it
PSA over 15